Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic Response of Foxy-5 in Patients With Metastatic Breast-, Colon- or Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Foxy 5 (Primary)
- Indications Breast cancer; Colon cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors WntResearch
- 07 Jun 2017 Biomarkers information updated
- 21 Mar 2017 Results published in WntResearch media release.
- 04 Jan 2017 Planned number of patients changed from 18 to 15.